[
  {
    "ts": null,
    "headline": "Hims & Hers Stock Surges on Wegovy Deal With Novo Nordisk",
    "summary": "Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk to bring weight-loss drug Wegovy to its customers.",
    "url": "https://finnhub.io/api/news?id=a2e6c2c7604e49d71feb45c71fab024ef8a85fd7e736cd1de734f9d708b34134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745944594,
      "headline": "Hims & Hers Stock Surges on Wegovy Deal With Novo Nordisk",
      "id": 134134121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk to bring weight-loss drug Wegovy to its customers.",
      "url": "https://finnhub.io/api/news?id=a2e6c2c7604e49d71feb45c71fab024ef8a85fd7e736cd1de734f9d708b34134"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Health: GLP-1 Deals De-Risk The Story",
    "summary": "Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ultra-bullish on HIMS stock.",
    "url": "https://finnhub.io/api/news?id=f878f678c3a10262262c53a6657b437390bfc85b349bdca63561034ea1dccceb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745940441,
      "headline": "Hims & Hers Health: GLP-1 Deals De-Risk The Story",
      "id": 134135524,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163791804/image_2163791804.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ultra-bullish on HIMS stock.",
      "url": "https://finnhub.io/api/news?id=f878f678c3a10262262c53a6657b437390bfc85b349bdca63561034ea1dccceb"
    }
  },
  {
    "ts": null,
    "headline": "INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales",
    "summary": "Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.",
    "url": "https://finnhub.io/api/news?id=edf8d4cae7db25079583e7167de26e51f339b1de40e3bef0c7f45b0e936dbdf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745939040,
      "headline": "INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales",
      "id": 134130889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.",
      "url": "https://finnhub.io/api/news?id=edf8d4cae7db25079583e7167de26e51f339b1de40e3bef0c7f45b0e936dbdf3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer offers 'longer-term' opportunity amid tariff uncertainty",
    "summary": "Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 billion in cost-cutting efforts, though the company says it's \"unable to predict\" the impact of US President Trump's tariffs. Guggenheim Securities senior research analyst and managing director Vamil Divan joins Brad Smith and Madison Mills on Morning Brief to take a closer look at Pfizer's earnings print. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=2e945d0fac06e36b13b4dcbafdc3f0063d9e730ce510745adfbe44a2580cad55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745937075,
      "headline": "Pfizer offers 'longer-term' opportunity amid tariff uncertainty",
      "id": 134130891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 billion in cost-cutting efforts, though the company says it's \"unable to predict\" the impact of US President Trump's tariffs. Guggenheim Securities senior research analyst and managing director Vamil Divan joins Brad Smith and Madison Mills on Morning Brief to take a closer look at Pfizer's earnings print. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=2e945d0fac06e36b13b4dcbafdc3f0063d9e730ce510745adfbe44a2580cad55"
    }
  },
  {
    "ts": null,
    "headline": "Growth Is Priced Out Of Novo Nordisk",
    "summary": "Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock prospects.",
    "url": "https://finnhub.io/api/news?id=3e3a2729b24fe4a72743ed23043f06f8ca2747b853450d9356a6e7de8c6aae8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745936975,
      "headline": "Growth Is Priced Out Of Novo Nordisk",
      "id": 134134947,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock prospects.",
      "url": "https://finnhub.io/api/news?id=3e3a2729b24fe4a72743ed23043f06f8ca2747b853450d9356a6e7de8c6aae8e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?",
    "summary": "NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.",
    "url": "https://finnhub.io/api/news?id=0f324226ff991d367fce806e5d94482811948385c6cfd13a5156fe9cd049787f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745936400,
      "headline": "Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?",
      "id": 134130893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.",
      "url": "https://finnhub.io/api/news?id=0f324226ff991d367fce806e5d94482811948385c6cfd13a5156fe9cd049787f"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership",
    "summary": "Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.",
    "url": "https://finnhub.io/api/news?id=fdf6045ad24c4fc3466ba22d145db8de7e87ff335e926286726c29fe0ffed8fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745936291,
      "headline": "Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership",
      "id": 134130894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.",
      "url": "https://finnhub.io/api/news?id=fdf6045ad24c4fc3466ba22d145db8de7e87ff335e926286726c29fe0ffed8fd"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly and Company (LLY): “Riding the wave of GLP-1 success” – Ready to Rebound After a Rare Miss",
    "summary": "We recently published a list of Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. On Friday, Mad Money host Jim Cramer took a close look at what […]",
    "url": "https://finnhub.io/api/news?id=de15b4d6b0ad6c23425c07a5b0fc98ffd0eb1ab059f8e62953762fcc74ccb37c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745930301,
      "headline": "Jim Cramer on Eli Lilly and Company (LLY): “Riding the wave of GLP-1 success” – Ready to Rebound After a Rare Miss",
      "id": 134130896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. On Friday, Mad Money host Jim Cramer took a close look at what […]",
      "url": "https://finnhub.io/api/news?id=de15b4d6b0ad6c23425c07a5b0fc98ffd0eb1ab059f8e62953762fcc74ccb37c"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Long-Term Dividend Stock to Buy According to Billionaires?",
    "summary": "We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every day and billionaire investors. A CNBC […]",
    "url": "https://finnhub.io/api/news?id=be2a3224ae1d505b565da80d545c26bb4cc6615ec2c5d1433d7aea63b45c3326",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745930152,
      "headline": "Is Eli Lilly and Company (LLY) the Best Long-Term Dividend Stock to Buy According to Billionaires?",
      "id": 134130897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every day and billionaire investors. A CNBC […]",
      "url": "https://finnhub.io/api/news?id=be2a3224ae1d505b565da80d545c26bb4cc6615ec2c5d1433d7aea63b45c3326"
    }
  },
  {
    "ts": null,
    "headline": "Novo partners with telehealth companies in move to expand Wegovy market",
    "summary": "Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no longer in shortage.",
    "url": "https://finnhub.io/api/news?id=33bde86ec398481e80420371e2f471c6b8931d6249158e18929e0c0a29faaeb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745928600,
      "headline": "Novo partners with telehealth companies in move to expand Wegovy market",
      "id": 134130898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no longer in shortage.",
      "url": "https://finnhub.io/api/news?id=33bde86ec398481e80420371e2f471c6b8931d6249158e18929e0c0a29faaeb3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Surpasses Q1 Earnings Estimates",
    "summary": "Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=724e61fce788f1ccd08ebb2c6641a61412a44dfee99b3aaf0ec93954819c4203",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745927704,
      "headline": "Pfizer (PFE) Surpasses Q1 Earnings Estimates",
      "id": 134130899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=724e61fce788f1ccd08ebb2c6641a61412a44dfee99b3aaf0ec93954819c4203"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Gets a Double Downgrade. Where Weight-Loss Drugs Go From Here.",
    "summary": "The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo Nordisk’s Ozempic .",
    "url": "https://finnhub.io/api/news?id=53cd7a726bf02785ad95db7285240c10497ee5d9bef7756be2efb928141672f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745927400,
      "headline": "Eli Lilly Stock Gets a Double Downgrade. Where Weight-Loss Drugs Go From Here.",
      "id": 134130900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo Nordisk’s Ozempic .",
      "url": "https://finnhub.io/api/news?id=53cd7a726bf02785ad95db7285240c10497ee5d9bef7756be2efb928141672f4"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q1 2025 Top Contributors And Detractors",
    "summary": "Baron Health Care Fund declined 2.54% in Q1 2025. Who were the leaders and laggards? Click here to find out.",
    "url": "https://finnhub.io/api/news?id=64360e2ab5d7c801187183c998d5cb1993bbd2f845ff25b1630d3ed1c274fe69",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745926200,
      "headline": "Baron Health Care Fund Q1 2025 Top Contributors And Detractors",
      "id": 134127928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345347757/image_1345347757.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Baron Health Care Fund declined 2.54% in Q1 2025. Who were the leaders and laggards? Click here to find out. ",
      "url": "https://finnhub.io/api/news?id=64360e2ab5d7c801187183c998d5cb1993bbd2f845ff25b1630d3ed1c274fe69"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook",
    "summary": "Pfizer missed first quarter earnings Thursday amid a volatile macro environment.",
    "url": "https://finnhub.io/api/news?id=0882452f2d8f35af59afb40c902e6139821291c5fad7d3b69f0291f64f9c2eb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745924256,
      "headline": "Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook",
      "id": 134130901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer missed first quarter earnings Thursday amid a volatile macro environment.",
      "url": "https://finnhub.io/api/news?id=0882452f2d8f35af59afb40c902e6139821291c5fad7d3b69f0291f64f9c2eb0"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron",
    "summary": "Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=b533d00f3cfcfab75996e6f61bdb4111f0bc92aa9dbf9d909f8cdf7ce7accfce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745922720,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron",
      "id": 134130902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=b533d00f3cfcfab75996e6f61bdb4111f0bc92aa9dbf9d909f8cdf7ce7accfce"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback",
    "summary": "Hims & Hers Health, Inc. teams up with Novo Nordisk to offer Wegovy at $599/month, slashing costs. Click for why this is a game-changing deal for HIMS stock.",
    "url": "https://finnhub.io/api/news?id=23b2cead4f5efd96c40e07985274fb1ae5832ca239374f21b036820e97a4478d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745922630,
      "headline": "Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback",
      "id": 134126044,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212300963/image_1212300963.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers Health, Inc. teams up with Novo Nordisk to offer Wegovy at $599/month, slashing costs. Click for why this is a game-changing deal for HIMS stock.",
      "url": "https://finnhub.io/api/news?id=23b2cead4f5efd96c40e07985274fb1ae5832ca239374f21b036820e97a4478d"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Soars. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.",
    "summary": "Hims & Hers Stock Soars. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.",
    "url": "https://finnhub.io/api/news?id=38a47f118df18fbb72de74f76f859745c7e7e5e0c6bf2c0fdf861667c11d8e98",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745920020,
      "headline": "Hims & Hers Stock Soars. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.",
      "id": 134146407,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Hims & Hers Stock Soars. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.",
      "url": "https://finnhub.io/api/news?id=38a47f118df18fbb72de74f76f859745c7e7e5e0c6bf2c0fdf861667c11d8e98"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers’ stock rockets after teaming up with its rival Wegovy maker",
    "summary": "Hims & Hers’ stock rockets after teaming up with its rival Wegovy maker",
    "url": "https://finnhub.io/api/news?id=7c838085e2c597343cd8ddc18f2e12fbb985e037ac6442484b3b1150820e7a6b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745917980,
      "headline": "Hims & Hers’ stock rockets after teaming up with its rival Wegovy maker",
      "id": 134126913,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Hims & Hers’ stock rockets after teaming up with its rival Wegovy maker",
      "url": "https://finnhub.io/api/news?id=7c838085e2c597343cd8ddc18f2e12fbb985e037ac6442484b3b1150820e7a6b"
    }
  }
]